10.00

0.10% -0.010

After Hours: 9.75 -0.25 -2.50%

Liquidia Corp (LQDA)

Overview News Price History Option Chain Financials Discussions Forecast

Liquidia Corp stock is traded at $10.00, with a volume of 531.83K. It is down -0.10% in the last 24 hours and up +5.15% over the past month. Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Previous Close:

$10.01

Open:

$9.91

24h Volume:

531.83K

Relative Volume:

0.44

Market Cap:

$843.78M

Revenue:

$17.49M

Net Income/Loss:

$-78.50M

P/E Ratio:

-12.99

EPS:

-0.77

Net Cash Flow:

$-52.85M

1W Performance:

+0.70%

1M Performance:

+5.15%

6M Performance:

-32.20%

1Y Performance:

+57.73%

1-Day Range:

$9.89

$10.19

1-Week Range:

$9.89

$10.48

52-Week Range:

$5.71

$16.99

Liquidia Corp Stock (LQDA) Company Profile

Name

Liquidia Corp

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

919.328.4400

Address

419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC

Employee

145

Twitter

@Liquidia_Inc

Next Earnings Date

2024-08-07

Latest SEC Filings

LQDA's Discussions on Twitter

Liquidia Corp Stock (LQDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-19-22	Resumed	Wedbush	Underperform
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform
Jul-22-22	Initiated	Ladenburg Thalmann	Buy
May-31-22	Initiated	BTIG Research	Buy
May-26-22	Initiated	BofA Securities	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform
Aug-20-18	Initiated	Jefferies	Buy
Aug-20-18	Initiated	Needham	Buy

View All

Liquidia Corp Stock (LQDA) Latest News

Sep 26, 2024

LQDA Stock Sees Surge of Approximately 4.04% in Last Five Days - Knox Daily

Sep 26, 2024

Sep 25, 2024

Liquidia Moves Again to Block FDA Exclusivity of UTC Lung Drug - Bloomberg Law

Sep 25, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia CorporationLQDA - PR Newswire

Sep 25, 2024

How to interpret Liquidia Corp (LQDA)’s stock chart patterns - US Post News

Sep 25, 2024

Sep 24, 2024

Daily Market Movement: Liquidia Corp (LQDA) Sees a -0.20 Decrease, Closing at 9.93 - The Dwinnex

Sep 24, 2024

Taking the lead: Liquidia Corp (LQDA) - SETE News

Sep 24, 2024

Sep 23, 2024

Raymond James upgrades Liquidia Corp (LQDA) rating to a Strong buy - Knox Daily

Sep 23, 2024

HighVista Strategies LLC Acquires Shares of 121,754 Liquidia Co. (NASDAQ:LQDA) - MarketBeat

Sep 23, 2024

Arizona State Retirement System Buys 1,341 Shares of Liquidia Co. (NASDAQ:LQDA) - Defense World

Sep 19, 2024

Sep 18, 2024

Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com Canada

Sep 18, 2024

Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com Australia

Sep 18, 2024

Sep 17, 2024

Liquidia Corp faces renewed legal challenge from United Therapeutics - Investing.com India

Sep 17, 2024

Liquidia Corp faces renewed legal challenge from United Therapeutics - Investing.com

Sep 17, 2024

Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com South Africa

Sep 17, 2024

Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com UK

Sep 17, 2024